Trial Profile

A Phase 1, Randomized, Double-Blind Study to Compare the Effect of Omadacycline PO Versus Moxifloxacin PO on the Gut Microbiota in Healthy Adult Volunteers

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 05 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Omadacycline (Primary) ; Moxifloxacin
Indications Anthrax; Bacterial infections; Community-acquired pneumonia; Cystitis; Nontuberculous mycobacterium infections; Pyelonephritis; Skin and soft tissue infections; Urinary tract infections
Focus Adverse reactions
Sponsors ZAI Lab

Most Recent Events

01 Nov 2024 Status changed from recruiting to completed.
14 Oct 2024 According to a Paratek Pharmaceuticals media release, a new data from this study will be presented at IDWeek 2024, Oct. 16-19 at the Los Angeles Convention Center in Los Angeles, CA.
19 Jun 2024 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com